Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9UMR2
UPID:
DD19B_HUMAN
Alternative names:
DEAD box RNA helicase DEAD5; DEAD box protein 19B
Alternative UPACC:
Q9UMR2; B3KNE9; B4DXS6; E7EMK4; Q6FIB7; Q6IAE0; Q96KE7; Q9H0U0
Background:
ATP-dependent RNA helicase DDX19B, also known as DEAD box protein 19B, plays a crucial role in mRNA export from the nucleus. It operates not by unwinding RNA duplexes but by remodeling ribonucleoprotein particles, facilitating the replacement of nuclear mRNA-bound proteins with cytoplasmic ones.
Therapeutic significance:
Understanding the role of ATP-dependent RNA helicase DDX19B could open doors to potential therapeutic strategies.